Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 326-335

  Ramirez, Trevi A ^a   Iyer, Rugmani Padmanabhan ^a   Ghasemi, Omid ^a,c   Lopez, Elizabeth F ^a   Levin, Daniel B ^a   Zhang, Jianhua ^a   Zamilpa, Rogelio ^a   Chou, Youn Min ^a,b   Jin, Yu Fang ^a,c   Lindsey, Merry L ^a,d  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c The University of Texas at San Antonio   (United States)

^d G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aliskiren; Extracellular matrix; MMP 9; Myocardial infarction; Remodeling; Valsartan

Indexed keywords

ALISKIREN; GELATINASE B; VALSARTAN; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FEMALE; GENE DELETION; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SURVIVAL RATE; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; KNOCKOUT MOUSE; MORTALITY; MYOCARDIAL INFARCTION; PATHOLOGY; SURVIVAL; SYSTOLE;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EXTRACELLULAR MATRIX; FEMALE; FUMARATES; GENE EXPRESSION; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL INFARCTION; MYOCARDIUM; STROKE VOLUME; SURVIVAL ANALYSIS; SYSTOLE; TETRAZOLES; VALINE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84901310496     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.04.007     Document Type: Article

References (40)

1. Gaudron P., Kugler I., Hu K., Bauer W., Eilles C., Ertl G. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their inter-relation and prognostic impact. J Am Coll Cardiol 2001, 38:33-40.
2. Iyer R.P., Patterson N.L., Fields G.B., Lindsey M.L. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 2012, 303:H919-H930.
3. Lindsey M., Wedin K., Brown M.D., Keller C., Evans A.J., Smolen J., et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 2001, 103:2181-2187.
4. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999, 15:3063-3070.
5. Villarreal F.J., Griffin M., Omens J., Dillmann W., Nguyen J., Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 2003, 108:1487-1492.
6. Lindsey M.L., Escobar G.P., Dobrucki L.W., Goshorn D.K., Bouges S., Mingoia J.T., et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 2006, 290:H232-H239.
7. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003, 107:1579-1585.
8. Kelly D., Khan S.Q., Thompson M., Cockerill G., Ng L.L., Samani N., et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008, 29:2116-2124.
9. Zamilpa R., Kanakia J., Cigarroa J., Dai Q., Escobar H., Martinez, Jimenez F., et al. CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2011, 300:H1418-H1426.
10. Muller D.N., Derer W., Dechend R. Aliskiren-mode of action and preclinical data. J Mol Med 2008, 86:659-662.
11. Muller D.N., Luft F.C. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006, 1:221-228.
12. Stegbauer J.L.D., Seubert S., Ellrichmann G., Manzel A., Kvakan H., Muller D.N., et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A 2009, 106:14942-14947.
13. Solomon S.D., Skali H., Bourgoun M., Fang J., Ghali J.K., Martelet M., et al. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. Am Heart J 2005, 150:257-262.
14. Fujiwara Y., Shiraya S., Miyake T., Yamakawa S., Aoki M., Makino H., et al. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med 2008, 22:703-708.
15. Vu T.H., Shipley J.M., Bergers G., Berger J.E., Helms J.A., Hanahan D., et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422.
16. Martin M.D., Carter K.J., Jean-Philippe S.R., Chang M., Mobashery S., Thiolloy S., et al. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 2008, 68:6251-6259.
17. Lindsey M.L., Dobrucki L.W., Bouges S., Mingoia J.T., McClister D.M., Su H., et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocaridal infarction. Am J Physiol Heart Circ Physiol 2006, 290:H232-H239.
18. Chiao Y.A., Dai Q., Zhang J., Lin J., Lopez E.F., Ahuja S.S., Chou Y.M., et al. Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet 2011, 4:455-463.
19. Michael L.H., Ballantyne C.M., Zachariah J.P., Gould K.E., Pocius J.S., Taffet G.E., et al. Myocardial infarction and remodeling in mice: effect of reperfusion. Am J Physiol 1999, 277:H660-H668.
20. Cheng Y., Church G.M. Biclustering of expression data. Proc Int Conf Intell Syst Mol Biol 2000, 8:93-103.
21. Zheng F., Zeng Y.J., Plati A.R., Elliot S.J., Berho M., Potier M., et al. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice. Kidney Int 2006, 70:507-514.
22. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., Rouleau J.-L., Køber L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl J Med 2003, 349:1893-1906.
23. Black H.R., Bailey J., Zappe D., Samuel R. Valsartan: more than a decade of experience. Drugs 2009, 69:2393-2414.
24. Gervais M., Richer C., Fornes P., De Gasparo M., Giudicelli J.F. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol 1999, 13:635-645.
25. Higashikuni Y., Takaoka M., Iwata H., Tanaka K., Hirata Y., Nagai R., et al. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. Hypertens Res Off Jpn Soc Hypertens 2012, 35:62-69.
26. Cho Y.R., Kim Y.D., Park T.H., Park K., Park J.S., Baek H., et al. The impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial. Trials 2011, 12:247.
27. Sun Y., Weber K.T. Infarct scar: a dynamic tissue. Cardiovasc Res 2000, 46:250-256.
28. Lijnen P.J., Petrov V.V., Fagard R.H. Induction of cardiac fibrosis by transforming growth factor-[beta]1. Mol Genet Metab 2000, 71:418-435.
29. Willems I., Havenith M., De Mey J., Daemen M. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol 1994, 145:868-875.
30. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005, 65:40-51.
31. Squires C.E., Escobar G.P., Payne J.F., Leonardi R.A., Goshorn D.K., Sheats N.J., et al. Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol 2005, 39:699-707.
32. Lijnen P.P.V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol 1999, 21:215-227.
33. Mervaala E.M., Muller D.N., Park J.K., Schmidt F., Lohn M., Breu V., Dragun D., et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999, 33:389-395.
34. Clarke N.E., FM, Porter K.E., Lambert D.W., Turner A.J. Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling. PLoS One 2012, 7:e34747.
35. Takafuji V.F.M., Unsworth E., Goldsmith P., Wang X.W. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 2007, 26:6361-6371.
36. Giles J.T., Fert-Bober J., Park J.K., Bingham C.O., Andrade F., Fox-Talbot K., et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther 2012, 14:R39.
37. Lambert J.M., Lopez E.F., Lindsey M.L. Macrophage roles following myocardial infarction. Int J Cardiol 2008, 130:147-158.
38. Li Q., Park P.W., Wilson C.L., Parks W.C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002, 111:635-646.
39. Suzuki T., Hashimoto S., Toyoda N., Nagai S., Yamazaki N., Dong H.Y., et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000, 96:2584-2591.
40. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276-283.